Trial · NCT00126191
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
NCT00126191, Phase 2, Terminated, Dana-Farber Cancer Institute; results first posted 2013-05-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma. Trials, record NCT00126191. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00126191
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
- NCT number
- NCT00126191
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- Dana-Farber Cancer Institute
- Conditions
- Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma
- Interventions
- Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Methotrexate, Leucovorin, Ifosfamide, Etoposide, Cytarabine, Mesna
- First posted
- 2005-08-03
- Last updated
- 2013-05-23
- Results first posted
- 2013-05-23
- Limitations and caveats
- Early termination leading to small numbers of subjects analyzed.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt | 3 years | Complete Response (CR): Disappearance of all measurable or evaluable disease confirmed. Partial Response (PR): Reduction of 50% or greater in the sum of the products of the perpendicular diameters of all measurable. Of 8 High Risk participants, 7 met the primary response outcome. 1 High Risk participant did not meet protocol defined primary outcome response and died two months following enrollment. |
| Secondary | Disease Free Survival | Until disease progression up to 120 months | Participants are followed after completion of protocol therapy until disease progression to determine disease free survival. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt | 3 years | participants | NUMBER | |
| SECONDARY | Disease Free Survival | Until disease progression up to 120 months | One low-risk participant was lost to follow-up after 48 months of disease free survival. | Months | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt | Low Risk | 2 | participants | ||
| Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt | High Risk | 7 | participants | ||
| Disease Free Survival | Low Risk | 84 | Full Range 84 to 84 | Months | |
| Disease Free Survival | High Risk | 52 | Full Range 2 to 83 | Months |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Low Risk | 2 | |
| Overall Study | STARTED | High Risk | 8 | |
| Overall Study | COMPLETED | Low Risk | 2 | |
| Overall Study | COMPLETED | High Risk | 6 | |
| Overall Study | NOT COMPLETED | Low Risk | 0 | |
| Overall Study | NOT COMPLETED | High Risk | 2 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Bilirubin | Metabolism and nutrition disorders | Low Risk | 1 | 2 | 1 |
| serious | Bilirubin | Metabolism and nutrition disorders | High Risk | 1 | 8 | 1 |
| serious | Fatigue | General disorders | Low Risk | 1 | 2 | 1 |
| serious | Fatigue | General disorders | High Risk | 1 | 8 | 1 |
| serious | Hyperuricemia | Endocrine disorders | Low Risk | 1 | 2 | 1 |
| serious | Hyperuricemia | Endocrine disorders | High Risk | 1 | 8 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Low Risk | ||
| Total, all-cause mortality | High Risk | ||
| Total, other adverse events | Low Risk | 0 | 2 |
| Total, other adverse events | High Risk | 0 | 8 |
| Total, serious adverse events | Low Risk | 1 | 2 |
| Total, serious adverse events | High Risk | 2 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Low Risk vs High Risk: Response Rates (CR and PR) in Adults With Burkitt/Atypical Burkitt | Trial comparisons |
| Low Risk vs High Risk: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00126191
GET https://conductscience.org/api/trials/v1/NCT00126191/registered